Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 25,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $34.57, for a total transaction of $864,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Gil M. Labrucherie also recently made the following trade(s):
- On Monday, June 17th, Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock. The stock was sold at an average price of $33.71, for a total transaction of $842,750.00.
- On Thursday, May 16th, Gil M. Labrucherie sold 3,767 shares of Nektar Therapeutics stock. The stock was sold at an average price of $31.37, for a total transaction of $118,170.79.
Shares of NKTR stock traded up $0.19 on Friday, reaching $33.72. 875,984 shares of the stock were exchanged, compared to its average volume of 1,663,484. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average price is $34.01. The stock has a market cap of $5.88 billion, a P/E ratio of 8.92 and a beta of 2.74. Nektar Therapeutics has a twelve month low of $29.22 and a twelve month high of $69.76.
Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. The firm had revenue of $28.22 million during the quarter, compared to the consensus estimate of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. On average, sell-side analysts anticipate that Nektar Therapeutics will post -3.14 earnings per share for the current year.
Several hedge funds have recently modified their holdings of NKTR. FMR LLC lifted its position in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after acquiring an additional 2,041,954 shares during the last quarter. Norges Bank purchased a new stake in Nektar Therapeutics in the fourth quarter valued at $63,723,000. Deutsche Bank AG lifted its position in Nektar Therapeutics by 131.6% in the fourth quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock valued at $31,125,000 after acquiring an additional 538,170 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Nektar Therapeutics in the fourth quarter valued at $10,638,000. Finally, Rhenman & Partners Asset Management AB raised its holdings in shares of Nektar Therapeutics by 42.6% in the first quarter. Rhenman & Partners Asset Management AB now owns 734,445 shares of the biopharmaceutical company’s stock valued at $24,677,000 after buying an additional 219,445 shares during the last quarter. Hedge funds and other institutional investors own 92.23% of the company’s stock.
Several research firms have commented on NKTR. Svb Leerink began coverage on shares of Nektar Therapeutics in a research note on Friday, March 15th. They issued a “mkt perform” rating and a $38.00 price target for the company. ValuEngine downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Monday, June 3rd. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, June 20th. Leerink Swann began coverage on shares of Synthorx in a research note on Friday, March 15th. They set an “outperform” rating for the company. Finally, Cowen set a $200.00 target price on shares of Lululemon Athletica and gave the stock a “buy” rating in a research note on Thursday, June 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. Nektar Therapeutics presently has an average rating of “Buy” and an average target price of $68.50.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: The Discount Rate – What You Need to Know
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.